Effect of l-asparaginase combined with vincristine and prednisolone on acute myeloblastic leukemia (MO) associated with non-hodgkin lymphoma

Acta Haematologica

Volumn 122, Issue 1, 2009, Pages 54-57

  Horikoshi, Akira ^a   Takei, Kazuhiro ^a   Iriyama, Noriyoshi ^a   Uenogawa, Kumi ^a   Ishizuka, Hikaru ^a   Shiraiwa, Hidetaka ^a   Hosokawa, Yoshifumi ^a   Sawada, Shigemasa ^a   Kitoh, Toshiyuki ^b  

^a NIHON UNIVERSITY   (Japan)

^b Shiga Medical Center for Children   (Japan)

Author keywords

Acute myeloblastic leukemia (M0); Asparagine synthetase; L Asparaginase; Non Hodgkin lymphoma

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; MONOCLONAL ANTIBODY; PREDNISOLONE; VINCRISTINE;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ANEMIA; ARTICLE; BLAST CELL; CASE REPORT; CHROMOSOME ANALYSIS; CLINICAL FEATURE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JAUNDICE; LYMPH NODE BIOPSY; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; ASPARTATE-AMMONIA LIGASE; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; PREDNISOLONE; REMISSION INDUCTION; VINCRISTINE;

EID: 70349844092     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000243725     Document Type: Article

References (28)

1. Rosner F, Grunwald H: Hodgkin's disease and acute leukemia: report of eight cases and review of the literature. Am J Med 1975; 58: 339-353.
2. Canellos GP, DeVita VT, Arseneau JC, Whan-Peng J, Johnson REC: Second malignancies complicating Hodgkin's disease in remission. Lancet 1975;1(7913):947-949.
3. Grunwald HW, Rosner F: Acute myeloid leukemia following treatment of Hodgkin's disease. Cancer 1982; 50: 676-683.
4. Zarrabi MH, Rosner F, Bennet JM: Non- Hodgkin's lymphoma and acute myeloblastic leukemia. Report of 12 cases and review of the literature. Cancer 1979; 44: 1070-1080.
5. Greene MH, Young RC, Merrill JM, DeVita VT: Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Res 1983; 43: 1891-1898.
6. Super HJG, McCabe NR, Thirman MJ, Larson RA, Le Beau MM, Pedersen-Bjergaard J, Phillip P, Diaz MO, Rowley JD: Rearrangement of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993; 82: 3705-3711.
7. Bergsagel DE, Bailey AJ, Langley GR, Mac- Donald RN, White DF, Miller AB: The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743-748.
8. Stern N, Shemesh J, Ramot B: Chronic lymphatic leukemia terminating in acute myeloid leukemia: review of the literature. Cancer 1981; 47: 1849-1851.
9. Kitoh T, Sawada M, Shirahase H, Hamahata K, Usami I, Ying-Wei L, Akiyama Y, Kubota M, Schuster SM: Asparagine synthetase protein expression in leukemia cells: application of L -asparaginase treatment for leukemia. Blood 1998; 92(suppl 1):400a.
10. Ota K, Ogawa N: Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults. Biomed Pharmacother 1990; 44: 93-102.
11. Kapadia SB, Kaplan SS: Simultaneous occurrence of non-Hodgkin's lymphoma and acute myelomonocytic leukemia. Cancer 1978; 38: 2257-2260.
12. Kjeldsberg CR, Nathwani BN, Rappaport H: Acute myeloblastic leukemia developing in patients with mediastinal lymphoblastic lymphoma. Cancer 1979; 44: 2316-2323.
13. Dumont I, Mayer M, Fievez M, Neve P: Acute myeloblastic leukemia occurring with an extranodal lymphoma: an unusual association. Acta Clin Belg 1983; 38: 128-133.
14. Jaalouk G, Avvisati G, Latagliata R, Pacchiarotti A, Pulsoni A, Mecarocci S, Malagnino F: Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and myelodysplastic syndrome rapidly evolving into acute myeloblastic leukemia. Leuk Lymphoma 1996; 21: 339-341.
15. Saxenia A, Sheridan DP, Card RT, McPeek AM, Mewdell CC, Skinnider LF: Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol 1998; 58: 278-284.
16. Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, Yagasaki F, Bessyo M, Sakamaki H, Dan K, Kuriya S: Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 2001; 115: 612-615.
17. Yamamoto K, Nagata K, Hamaguchi H: A new case of CD7-positive acute myeloblastic leukemia with trisomy 21 as a sole acquired abnormality. Cancer Genet Cytogenet 2002; 133: 183-184.
18. Baer MR, Stewart CC, Lawrence D, Arthur DC, Byrd JC, Davey FR, Schiffer CA, Bloomfield CD: Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8; 21)(q22;q22). Blood 1997; 90: 1643-1648.
19. Raspadori D, Damiani D, Lenoci M, Rondelli D, Testoni N, Nardi G, Sestigiani C, Mariotti C, Birtolo S, Tozzi M, Lauria F: CD56 antigen expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001; 15: 1161-1164.
20. Suzuki R, Murata M, Kami M, Ohtake S, Asou N, Kodera Y, Tomonaga M, Masaki Y, Kusumoto S, Takeuchi J, Matsuda S, Hirai H, Yorimitsu S, Hamajima N, Seto M, Shimoyama M, Ohno R, Morishima Y, Nakamura S: Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol 2003; 77: 482-489.
21. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y: Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol 2005; 79: 39-41.
22. Law IP, Blom J: Second malignancies in patients with multiple myeloma. Oncology 1977; 34: 20-24.
23. Grulich AE, Li Y, McDonald A, Correl PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16: 1155-1161.
24. Capizzi RL, Bertino JR, Skeel RT: L -Asparaginase: clinical, biochemical, pharmacological and immunological status. Ann Intern Med 1971; 74: 893-901.
25. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB: L -Asparaginase resistance in human leukemia - asparagine synthetase. Biochem Pharmacol 1969; 18: 2578-2580.
26. Aleskog A, Larsson R, Hoglund M, Kristensen J, Nygren P, Lindhagen E: In vitro drug resistance in B cell chronic lymphocytic leukemia: a comparison with acute myelocytic and acute lymphocytic leukemia. Anticancer Drugs 2005; 16: 277-283.
27. Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A: Clinical results of treatment with E. coli L -asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer 1970; 25: 279-305.
28. Capizzi RL, Davis R, Powell B, Cuttner J, Ellison RR, Cooper RR, Dillman R, Major WB, Dupre E, Mcintyre OR: Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia - a Cancer and Leukemia Group B Study. J Clin Oncol 1988; 6: 499-508.